<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221122056575N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-24</date_registration>
      <primary_sponsor>Oroumia University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of two types of time restricted eating on glycemic, lipid indices, appetite, and sleep quality of women with polycystic ovary syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of two types of time restricted eating on glycemic, lipid indices, appetite, and sleep quality of women with polycystic ovary syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66984</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method is used to equalize the sample size in the group step by step and in intervals called defined blocks, because in the simple randomization method, when the sample size is small, the sample is not balanced in the study arms. For this purpose, the online software for this type of randomization was used in the following link:

https://www.sealedenvelope.com/simple-randomiser/v1/lists

In this multimeter online software, including a total sample of 75 people, the number of groups (the names of the groups with capital letters A, B, C) and the number of blocks (the number of 3 blocks in the sizes of 3 and 6) were defined. Finally, by running the program, it gave us a random output list in which the sequence of people entering the study is shown. Because in the present study, the samples are gradually entered into the study, determining the sequence and the order of people's entry into the groups is carried out with this method, and the researcher performs the random allocation sequence of this list. In other words, each new person enters the study without research and is selected from his place in the target group, and according to this list, he places his samples in the target group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Polycystic Ovary Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: People in the intervention groups will have a time-restricted eating of the type (14:10), in which people in the early time restricted eating (eTRE) group will be in a state of free consumption of food from 8:00 to 18:00. These people have been fasting for 14 hours and are only allowed to receive water and tea without sweets. Intervention 2: Intervention group: People in the intervention groups will have a time-restricted eating (14:10), in which the people in the mid-day time restricted eating (mTRE) group will eat freely from 11:00 to 21:00. Food is placed. These people have been fasting for 14 hours and are only allowed to receive water and tea without sweets. Intervention 3: Control group: People will continue their usual diet and there will be no time limit.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Due to confidentiality of participant information, it is not possible to publish it</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sevana Daneghian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Orjhans Street, Resalat Blvd, Urmia , Iran</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5714783734</zip>
        <telephone>+98 44 3223 4897</telephone>
        <email>Sevana_d@yahoo.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sevana Daneghian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Orjhans Street, Resalat Blvd, Urmia , Iran</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>571478334</zip>
        <telephone>+98 44 3223 4897</telephone>
        <email>Sevana_d@yahoo.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 - 40 years
25 ≤ body mass index(BMI) ≤ 34.9
Women with PCOS diagnosed by the Rotterdam criteria</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>pregnant or lactating
night-shift workers, 
hypotension
use of medication therapy that impacts carbohydrate or lipid metabolism (oral contraceptive pills, insulin-sensitizers, antiepileptics, statins, fish oil and ...) in the recent 3 months
body weight fluctuations for more than 5% in the past 3 months
Medicines that affect body weight
Regular use of any drug or supplement that affects sleep
Taking drugs that affect appetite at the time of entering the study
Having a special diet
Eating disorders or mental disorders
night eating syndrome
fasting for more than 14 h per day
Congenital adrenal hyperplasia, androgen-secreting tumor, Cushing's syndrome, diabetes, thyroid dysfunction and hyperprolactinemia
Cardiovascular, kidney, liver, lung and nervous diseases, digestive system surgery or food absorption disorders
professional athlete
perimenopausal
Tobacco history
Taking food supplements
Sarcopenia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: People in the intervention groups will have a time-restricted eating of the type (14:10), in which people in the early time restricted eating (eTRE) group will be in a state of free consumption of food from 8:00 to 18:00. These people have been fasting for 14 hours and are only allowed to receive water and tea without sweets.</i_keyword>
      <i_keyword>Intervention group: People in the intervention groups will have a time-restricted eating (14:10), in which the people in the mid-day time restricted eating (mTRE) group will eat freely from 11:00 to 21:00. Food is placed. These people have been fasting for 14 hours and are only allowed to receive water and tea without sweets.</i_keyword>
      <i_keyword>Control group: People will continue their usual diet and there will be no time limit.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fasting Blood Sugar. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Biochemical analysis of blood sample.</prim_outcome>
      <prim_outcome>Fasting Insulin. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Biochemical analysis of blood sample.</prim_outcome>
      <prim_outcome>Insulin resistance. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Calculation of Homeostatic Model Assessment (HOMA).</prim_outcome>
      <prim_outcome>Total cholesterol. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Biochemical analysis of blood sample.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Biochemical analysis of blood sample.</prim_outcome>
      <prim_outcome>High-density lipoprotein (HDL). Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Biochemical analysis of blood sample.</prim_outcome>
      <prim_outcome>Low-density lipoprotein (LDL). Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Biochemical analysis of blood sample.</prim_outcome>
      <prim_outcome>Appetite. Timepoint: beginning, middle and end of study (every two weeks). Method of measurement: Visual Analog Scale (VAS) questionnaire.</prim_outcome>
      <prim_outcome>Sleep quality. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Petersburg’s sleep quality questionnaire.</prim_outcome>
      <prim_outcome>Body weight. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: scale.</prim_outcome>
      <prim_outcome>Waist circumference. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Meter.</prim_outcome>
      <prim_outcome>Body mass index (BMI). Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Weight in kilograms divided by height squared in meters.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body composition. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: Bioelectric Impedance Analysis (BIA) device.</sec_outcome>
      <sec_outcome>Eating behavior. Timepoint: At the beginning and end of the study (after 6 weeks). Method of measurement: The Three-Factor Eating Questionnaire.</sec_outcome>
      <sec_outcome>Energy intake. Timepoint: beginning, middle and end of study (every two weeks). Method of measurement: 24-hour Dietary Recall.</sec_outcome>
      <sec_outcome>Carbohydrate intake. Timepoint: beginning, middle and end of study (every two weeks). Method of measurement: 24-hour Dietary Recall.</sec_outcome>
      <sec_outcome>Protein intake. Timepoint: beginning, middle and end of study (every two weeks). Method of measurement: 24-hour Dietary Recall.</sec_outcome>
      <sec_outcome>Fat intake. Timepoint: beginning, middle and end of study (every two weeks). Method of measurement: 24-hour Dietary Recall.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Urmia University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-16</approval_date>
        <contact_name>Research ethics committee of Urmia University of Medical Sciences</contact_name>
        <contact_address>Boostan dormitory, Zaker St, Apadana Crossroad, Urmia City, West Azarbaijan Urmia West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
